Lowey Dannenberg Notifies Maravai Lifesciences Holdings, Inc. (“Maravai” Or The “Company”) (NASDAQ: MRVI) Investors Of Securities Class Action Lawsuit And Encourages Investors With More Than $50,000 In Losses To Contact The Firm
On March 3, 2025, a complaint was filed against the Company and certain of its officers, alleging that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Maravai lacked adequate internal controls over financial reporting related to revenue recognition; (2) as a result, the Company inaccurately recognized revenue on certain transactions during fiscal 2024; (3) its goodwill was overstated; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
When investors learned the truth, Maravai's common stock declined precipitously, injuring investors.
If you suffered a loss of more than $50,000 in Maravai's securities, and wish to participate, or learn more, click here , or please contact our attorneys at (914) 733-7256 or via email to Andrea Farah (... ) or Vincent R. Cappucci Jr. (... ).
Any investor who wishes to serve as Lead Plaintiff must act before May 5, 2025 .
About Lowey Dannenberg
Lowey Dannenberg is a national firm representing institutional and individual investors, who suffered financial losses resulting from corporate fraud and malfeasance in violation of federal securities and antitrust laws. The firm has significant experience in prosecuting multi-million-dollar lawsuits and has recovered billions of dollars on behalf of its clients.
Contact:
Lowey Dannenberg P.C.
44 South Broadway, Suite 1100
White Plains, NY 10601
Tel: (914) 733-7234
Email: ...
SOURCE: Lowey Dannenberg P.C.

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.

Comments
No comment